ChemicalBook
Chinese English Japanese Germany Korea

Miglitol

Miglitol 구조식 이미지
카스 번호:
72432-03-2
상품명:
Miglitol
동의어(영문):
GLYSET;Miglito;Seibule;MIGLITOL;Plumarol;BAY 1099;Diastabol;BAY-m-1099;Miglitol(TCI);Miglitol (Glyset)
CBNumber:
CB2742795
분자식:
C8H17NO5
포뮬러 무게:
207.22
MOL 파일:
72432-03-2.mol

Miglitol 속성

녹는점
114°C
저장 조건
-20°C Freezer
산도 계수 (pKa)
5.9(at 25℃)
수용성
Soluble
Merck
14,6187
InChIKey
IBAQFPQHRJAVAV-ULAWRXDQSA-N
CAS 데이터베이스
72432-03-2(CAS DataBase Reference)

안전

WGK 독일 3
RTECS 번호 TN4350170
HS 번호 29333990

Miglitol C화학적 특성, 용도, 생산

개요

Miglitol was introduced in Germany as an auxiliary treatment for non-insulin dependent diabetes (NIDDM). A simple two-step synthesis of Miglitol consists of converting 6-desoxy-6-aminosorbose into desoxynojirimycin by reductive cyclization, then selectively hydroxyethylating the cyclic nitrogen. Miglitol is a short-acting intestinal alpha-D-glucosidase inhibitor, reducing postprandial glucose excursions by helping to delay absorption of complex carbohydrates. Acarbose and voglibose are the previous compounds marketed in this class. At low doses, orally administered miglitol was shown to be rapidly and completely absorbed then removed by renal excretion.

화학적 성질

white to light yellow crystal powde

Originator

Bayer (Germany)

용도

An inhibitor of alpha-glucosidases.

용도

A potent α-glucosidase inhibitor. A new antidiabetic drug.

용도

antibacterial

Indications

Miglitol [Glyset] is the second alpha-glucosidase inhibitor approved in the United States. Like acarbose, miglitol delays conversion of oligosaccharides and complex carbohydrates to glucose and other monosaccharides, and thereby reduces the postprandial rise in blood glucose. In clinical trials, the drug was especially effective among Latinos and African Americans. Hypoglycemia does not occur with miglitol monotherapy, but may occur if the drug is combined with insulin or a sulfonylurea. Like acarbose, miglitol causes flatulence, abdominal discomfort, and other GI effects. In contrast to acarbose, miglitol has not been associated with liver dysfunction. As with acarbose therapy, oral sucrose cannot be used to treat hypoglycemia. Rather, oral glucose must be given. Miglitol is available in 25-, 50-, and 100-mg tablets. The initial dosage is 25 mg 3 times daily before meals. The maintenance dosage is 50 or 100 mg 3 times a day.

생산 방법

Miglitol requires 1-deoxynojirimycin as a precursor which can be obtained via three different routes: extraction from plants such as the mulberry tree, fermentation using various bacterial strains, and a complete chemical synthesis. Industrially feasible production of miglitol was, however, restricted by expensive purification steps or low yields. Hence, a new approach was adopted in which a combination of biochemical and chemical synthesis was employed (Schedel, 2000). In this approach, D-glucose is converted to 1-amino-D-sorbitol by reduction with suitable amines and hydrogen, with nickel as catalyst, and then further reaction of products with appropriate acid esters (Kinast and Schedel, 1979). The oxidation of 1-amino-D-sorbitol to 6-amino-L-sorbose is then carried out in a fermenter using Gluconobacter oxydans grown at temperatures between 20 and 45 C, preferably at roomtemperature and maintaining thepHbetween 2.0 and 9.0. At this pH, 6-amino-L-sorbose is present in the medium as piperidinose, which is reduced to 1-desoxy-nojirimycin in the presence of inert solvents and by choosing the appropriate pH. After this, miglitol is obtained by first centrifuging the biomass followed by clarification using active charcoal. Next, separation of catalyst, evaporation of solvents, and isolation of any remaining salts in the medium is carried out (Kinast and Schedel, 1979). An important modification necessary in this process is the addition of protection groups before feeding 1-amino-D-sorbitol to the G. oxydans cultures and their subsequent removal before the ring-closure reaction. This is necessary since1-amino-D-sorbitol is readily oxidized by G. oxydans strains to form 3-hydroxy-2-hydroxymethyl-pyridine at near-neutral pH as a result of spontaneous ring closure (Schedel, 2000).

상표명

Glyset (Pharmacia & Upjohn);Diastabol.

일반 설명

Miglitol is (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol, or N-hydroxyethyl-1-deoxynorjirimycin. The drug is available as 25-, 50-, and100-mg tablets (Glyset), for administration 25 to 100 mgt.i.d. with meals. In contrast to acarbose, miglitol is highlyabsorbed from a 25-mg oral dose, although absorption is reportedto be saturable, and accordingly less complete athigher doses. Binding to plasma proteins is minimal, andthe volume of distribution (0.18 L/kg, corresponding to12–13 L in a 70-kg adult) is characteristic of compoundsdistributed only to blood and extracellular fluids. Practicallyno systemic biotransformation of miglitol occurs in humans;essentially 100% of an orally administered dose is excretedintact in urine.

일반 설명

Miglitol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-[2R-(2α,3β ,4α,5β)]-piperidine (Glyset), a desoxynojirimycinderivative, is chemically known as 3,4,5-piperidinetriol. It is a white to pale yellow powder that issoluble in water, with a pKa of 5.9. In chemical structure,this agent is very similar to a sugar, with the heterocyclic nitrogenserving as an isosteric replacement of the sugar oxygen.This feature allows recognition by the -glucosidase asa substrate. This results in competitive inhibition of the enzymeand delays complex carbohydrate absorption from thegastrointestinal tract.

Mechanism of action

The mechanism of action of miglitol is very similar to that of acarbose; it has strong binding affinity to digestive enzymes and, as a result, prevents these enzymes from binding to complex carbohydrates thereby delaying glucose absorption and resulting in reduction in postprandial plasma levels. The difference to note is that miglitol is a competitive inhibitor of digestive enzymes as a substitute for glucose, whereas acarbose functions as a substitute for the starch and oligosaccharides. Miglitol shows inhibitory action toward almost all the digestive enzymes present in the brush border of small intestine with the following ranking order: sucrase > glucoamylase > isomaltase > lactase > trehalase, and some inhibitory activity toward a-amylase (Lembcke et al., 1985; Scott and Spencer, 2000).
Both acarbose and voglibose are not absorbed in the upper section of upper intestine. Miglitol, however, is almost completely absorbed in the small intestine (Scott and Spencer, 2000; Tan, 1997). The absorption of miglitol is dose dependent, with 25 mg of miglitol rapidly and completely absorbed. However, higher doses of up to 100 mg do not get fully absorbed, and 95% of miglitol is excreted out of the system via urine and feces almost unchanged. The amount excreted depends upon the systemic absorption, and therefore on the dose administered. With the lowest dose of 25 mg, almost 95% excretion is achieved, but with higher dosages this amount drops. The half-life of miglitol in healthy volunteers is 2–3 h for a less potent dose of 50 mg (Ahr et al., 1997; Campbell et al., 2000; Scott and Spencer, 2000).

Clinical Use

One of the widely used a-glucosidase inhibitors for treatment of Type II diabetes is miglitol (C8H17NO5; IUPAC name (2R,3R,4R,5S)-1-(2-hydroxyethyl)- 2-(hydroxymethyl)piperidine-3,4,5-triol; molecular weight 207.2). Miglitol is a second-generation a-glucosidase inhibitor derived from 1-deoxynojirimycin, which is yet another a-glucosidase inhibitor and is structurally similar to glucose (Tan, 1997). It is a white to pale yellow powder and is soluble in water (Campbell et al., 2000). Miglitol was approved by the U.S. Food and Drug Administration (FDA) in 1996 as an additional therapy to diet alone therapy or diet plus sulfonylurea therapy in patients with Type II diabetes. Miglitol’s story begins with the successful attempts for identifying new compounds with inhibitory properties, which initially resulted in the discovery of nojirimycin, deoxynojirimycin, and their derivatives from various Bacillus and Streptomyces strains (Schmidt et al., 1979). During initial attempts, 1-deoxynojirimycin was successfully obtained (Schmidt et al., 1979); however, its N-hydroxyethyl analog (miglitol) later proved to possess better inhibitory activities. It is currently being manufactured by Bayer AG under the trade name of Glysetò in USA and as Diastabolò in Europe. Miglitol is considered to be a good choice for the therapy of patients who have the relative risk of developing hypoglycemia, weight gain, or lactic acidosis (Campbell et al., 2000). It is observed to have the same efficacy as acarbose at lesser dosages (50 and 100 mg tid). Miglitol therapy provides better reduction on fasting and postprandial plasma glucose levels in patients in comparison with sulfonylureas (Scott and Spencer, 2000), whereas voglibose, another a-glucosidase inhibitor, could achieve reduction only for postprandial glucose levels.

Chemical Synthesis

1-Deoxynojirimycin and its N-substituted analog N-hydroxyethyl-1- deoxynojirimycin (miglitol) are strong inhibitors of α-glucosidases and are used for the treatment of non-insulin-dependent diabetes (Campbell et al., 2000). The industrial production of these compounds follows a combined biotechnological- chemical synthesis, whereby G. oxydans plays a key-role in the oxidation of 1-aminosorbitol derivatives. As Gluconobacter cannot grow on aminopolyols, whole resting cells (grown on sorbitol) have to be used for this biotransformation process.

SYNTHESIS OF 1-DEOXYNOJIRIMYCIN AND MIGLITOL

Miglitol 준비 용품 및 원자재

원자재

준비 용품


Miglitol 공급 업체

글로벌( 182)공급 업체
공급자 전화 팩스 이메일 국가 제품 수 이점
Jinan Shengqi pharmaceutical Co,Ltd
86+18663751872
christine@shengqipharm.com CHINA 556 58
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19918 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21676 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20672 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32447 55
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3623 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30001 58
Shenzhen Nexconn Pharmatechs Ltd
15013857715
admin@nexconn.com CHINA 3195 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23980 58

Copyright 2019 © ChemicalBook. All rights reserved